Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice

Fig. 2

hAMSCs alleviates liver fibrosis and improves liver function in liver fibrosis mice. A The schematic diagram represents the experimental design regarding the induction of fibrosis and cell administration. B The distribution of GFP-labeled hAMSCs in vivo of liver fibrosis mice on day 7 or day 14 after transplantation. hAMSCs mainly distribution in the lung and liver. C The representative images of gross morphology of livers of control, PBS, and hAMSCs group. D Sirius Red Staining showing the degree of fibrosis in mice from different groups. E Quantitative analysis of the collagen area percentage in livers of different groups as shown in (D). F The serum levels of TBIL, ALT, AST, ALB, and ALP in each group. *P < 0.05, *P < 0.01, ***P < 0.001

Back to article page